Acta Haematologica最新文献_第5页

Prevalence of Pre-Treatment Sarcopenia in Patients Newly Diagnosed with Lymphoma. 新诊断淋巴瘤患者治疗前肌肉减少症的患病率。

IF 1.7 4区医学

Acta Haematologica Pub Date : 2025-04-05 DOI: 10.1159/000545358

Charlotte Nørregaard Grønset, Mary Jarden, Jan Christensen, Martin Hutchings, Anders Tolver, Charlotte Suetta

引用次数: 0

Acquired FX Deficiency in Multiple Myeloma without Concomitant Amyloidosis: A Rare Case Report. 无淀粉样变的多发性骨髓瘤获得性FX缺乏一例罕见病例报告。

IF 1.7 4区医学

Acta Haematologica Pub Date : 2025-03-29 DOI: 10.1159/000545479

Roi Gat, Svetlana Trestman, Ilya Kirgner

引用次数: 0

Acute Promyelocytic Leukemia Presenting with Cranial Nerve Involvement and Clivus Mass. 以脑神经受累和斜坡肿块为表现的急性早幼粒细胞白血病。

IF 1.7 4区医学

Acta Haematologica Pub Date : 2025-03-29 DOI: 10.1159/000545444

Ananya Chandrika Nanduri, Farah Ashraf, Swe Swe Hlaing, Michael Brister, Tapan M Kadia, Naveen Pemmaraju, Tulin Budak-Alpdogan

{"title":"Acute Promyelocytic Leukemia Presenting with Cranial Nerve Involvement and Clivus Mass.","authors":"Ananya Chandrika Nanduri, Farah Ashraf, Swe Swe Hlaing, Michael Brister, Tapan M Kadia, Naveen Pemmaraju, Tulin Budak-Alpdogan","doi":"10.1159/000545444","DOIUrl":"10.1159/000545444","url":null,"abstract":"Introduction: Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia that has become highly curable with advances in targeted therapy. However, central nervous system (CNS) involvement is exceedingly rare in APL and presents significant therapeutic challenges due to the limited penetrance of standard therapies across the blood-brain barrier (BBB). While APL is traditionally managed without chemotherapy, cases with CNS involvement require a multimodal approach for effective disease control.Case presentation: We present a unique case of a 31-year-old male with de novo APL and CNS involvement at the presentation, including a clival mass. The patient was successfully treated with a combination of systemic chemotherapy, intrathecal chemotherapy, and craniospinal irradiation, leading to durable remission.Conclusion: This case highlights the rarity of CNS involvement in APL and underscores the importance of a multidisciplinary approach in its management. Additionally, it emphasizes the need to address logistical barriers to treatment to achieve optimal patient outcomes.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-7"},"PeriodicalIF":1.7,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143750660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mind-Body Intervention in Chronic Lymphocytic Leukemia during the Watch-and-Wait Phase: Benefits Linked to Intervention Duration. 慢性淋巴细胞白血病在观察和等待阶段的身心干预：与干预时间有关的益处。

IF 1.7 4区医学

Acta Haematologica Pub Date : 2025-03-24 DOI: 10.1159/000545407

Shirley Shapira, Barak Mizrahi, Naama Hirschberger, Noa Rabinowicz, Adi Zoref-Lorenz, Natalie Flaks-Manov

{"title":"Mind-Body Intervention in Chronic Lymphocytic Leukemia during the Watch-and-Wait Phase: Benefits Linked to Intervention Duration.","authors":"Shirley Shapira, Barak Mizrahi, Naama Hirschberger, Noa Rabinowicz, Adi Zoref-Lorenz, Natalie Flaks-Manov","doi":"10.1159/000545407","DOIUrl":"10.1159/000545407","url":null,"abstract":"Introduction: Mind-body interventions (MBIs) are therapeutic practices that target the interactions between cognitive, emotional, and physiological systems to influence health outcomes. Previously, we demonstrated that MBI prolonged lymphocyte doubling time and treatment-free survival (TFS) in treatment-naïve chronic lymphocytic leukemia (CLL) patients during the watch-and-wait phase. In this follow-up study, we investigated the long-term effects of MBI on TFS after the intervention ceased.Methods: Sixty participants from the initial study (34 who received intervention vs. 26 controls) were followed for an additional period of 20 months. TFS was assessed from the end of the intervention to the initiation of CLL therapy or death, using Kaplan-Meier analysis and the log-rank test.Results: By the end of the follow-up, 9 participants who previously received MBI and 6 controls initiated CLL treatment. No significant difference in TFS was found between the groups (log-rank test, p = 0.65).Conclusion: While MBI provided a clear advantage as long as it continued, our follow-up analysis suggests this effect diminishes after the intervention ends. Continuous or repeated MBI may be necessary for sustained improvements in TFS.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-4"},"PeriodicalIF":1.7,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143699311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Bibliometric Analysis of Immunotherapy in Diffuse Large B-Cell Lymphoma from 2004 to 2024. 2004 - 2024年弥漫性大b细胞淋巴瘤免疫治疗的文献计量学分析。

IF 1.7 4区医学

Acta Haematologica Pub Date : 2025-03-21 DOI: 10.1159/000545152

Yanling Wu, Xiaomin Chen, Yang Liu, Yu Zhao, Lixiu Luo, Qiuwen Mi, Xiaoying Wen, Chunlan Huang

{"title":"A Bibliometric Analysis of Immunotherapy in Diffuse Large B-Cell Lymphoma from 2004 to 2024.","authors":"Yanling Wu, Xiaomin Chen, Yang Liu, Yu Zhao, Lixiu Luo, Qiuwen Mi, Xiaoying Wen, Chunlan Huang","doi":"10.1159/000545152","DOIUrl":"10.1159/000545152","url":null,"abstract":"Introduction: Immunotherapy in DLBCL (diffuse large B-cell lymphoma) disease has become an active research area with great value and potential. However, bibliometric research in this area is still sparse. Through bibliometric analysis, we aimed to visualize the research hot spots and trends of immunotherapy in DLBCL disease to help understand the future development of basic and clinical research.Methods: The Web of Science Core Collection database was searched for articles and reviews related to the immunotherapy of DLBCL from 2004 to 2024. VOSviewers, CiteSpace, and the R package \"bibliometrix\" were used to conduct the bibliometric analysis.Results: A total of 662 articles were included. The number of immunotherapy treatments in DLBCL increased year by year. The publications came from 55 countries, led by the USA and the People's Republic of China, and 1,349 institutions, with the leading research institutions being The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center. Leukemia & Lymphoma is the journal with the most research, and Blood is the journal with the most co-citations. We identified 4,833 authors, among which Young and Ken H. had the most significant articles, while Neelapu S.S. had the largest number of co-citations. After analysis, the most common keyword is CAR T (CAR T cells: chimeric antigen receptor T-cell immunotherapy, a current and developing area of research.Conclusions: This is the first bibliometric study to comprehensively summarize research trends and advances in immunotherapy in DLBCL disease. This information will provide a reference for researchers and healthcare providers in immunotherapy research by clarifying recent research frontiers and hot spots such as CAR T cells, bispecific antibodies, and so on.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-19"},"PeriodicalIF":1.7,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143690688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Effect of T-Lymphocyte Subgroups at Diagnosis on the Prognosis of Chronic Lymphocytic Leukemia. 诊断时t淋巴细胞亚群对慢性淋巴细胞白血病预后的影响。

IF 1.7 4区医学

Acta Haematologica Pub Date : 2025-03-17 DOI: 10.1159/000545269

Deniz Seyithanoglu, Esra Nazligul Sert, Murat Ozbalak, Metban Mastanzade, Simge Erdem, Mustafa N Yenerel

{"title":"The Effect of T-Lymphocyte Subgroups at Diagnosis on the Prognosis of Chronic Lymphocytic Leukemia.","authors":"Deniz Seyithanoglu, Esra Nazligul Sert, Murat Ozbalak, Metban Mastanzade, Simge Erdem, Mustafa N Yenerel","doi":"10.1159/000545269","DOIUrl":"10.1159/000545269","url":null,"abstract":"Introduction: Changes in the number and functional capacity of T lymphocytes have been reported in chronic lymphocytic leukemia (CLL) patients. The aim of this study was to examine the prognostic significance of T-lymphocyte subgroups in CLL patients.Methods: Eighty-three previously untreated patients were retrospectively enrolled and flow cytometry results at diagnosis were examined. No difference was found in T-lymphocyte parameters according to age, gender, and disease stage.Results: The CD4 and CD7 percentages, CD4/MBC (malignant B cell), CD8/MBC, and CD7/MBC values at diagnosis were significantly lower in patients with a progressive disease. T-lymphocyte percentages were significantly lower in deceased patients. In the univariate regression model, T-lymphocyte percentages, T-lymphocyte/MBC ratios, HLA-DR+ percentage, Rai stage (intermediate + high risk), Binet stage (B+C), and beta-2 microglobulin level had significant effects on both progression-free survival (PFS) and overall survival (OS); treatment status (yes) had a significant effect only on PFS, while age at diagnosis (≥65 years) had a significant effect only on OS. In the multivariate regression model, Rai stage, CD7/MBC ratio, and treatment status (yes) had a significant effect on PFS; Rai stage and CD8/MBC ratio had a significant effect on OS.Conclusion: Lower T-lymphocyte/MBC ratios at diagnosis could be a marker for higher risk of CLL progression.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-10"},"PeriodicalIF":1.7,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12060829/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hematological Evaluation and Management of Menorrhagia in Adolescents: Lessons from Adolescent Heavy Menstrual Bleeding Clinics. 青少年月经过多的血液学评估和管理：青少年大量月经出血诊所的经验教训。

IF 1.7 4区医学

Acta Haematologica Pub Date : 2025-03-15 DOI: 10.1159/000545299

Marganit Benish, Adi Shitrit Yarhi, Ivan Budnik, Chagit Klieger, Noah Gruber, Yael Harel, Gili Kenet, Assaf Arie Barg, Sarina Levy-Mendelovich

{"title":"Hematological Evaluation and Management of Menorrhagia in Adolescents: Lessons from Adolescent Heavy Menstrual Bleeding Clinics.","authors":"Marganit Benish, Adi Shitrit Yarhi, Ivan Budnik, Chagit Klieger, Noah Gruber, Yael Harel, Gili Kenet, Assaf Arie Barg, Sarina Levy-Mendelovich","doi":"10.1159/000545299","DOIUrl":"10.1159/000545299","url":null,"abstract":"Introduction: Heavy menstrual bleeding (HMB) poses a significant concern among adolescents and can arise from bleeding disorders. This study aimed to compare the clinical presentations and treatment of adolescents with HMB, distinguishing those with and without an underlying bleeding disorder.Methods: We conducted a retrospective analysis of adolescent patients presenting with HMB during 2014-2022 at specialized hematology-adolescent clinics in two tertiary referral hospitals in Israel. The study was approved by the Institutional Review Boards.Results: Seventy-seven adolescents underwent evaluation for HMB, and 19 of them were diagnosed with various bleeding disorders: platelet aggregation defects (5), immune thrombocytopenia (1), Glanzmann thrombasthenia (1), VWD type 1 (5), type 2 A (1), type 3 (3), and coagulation factor deficiencies (3). Notably, 38 patients (49%) were hospitalized. A higher bleeding score (BAT) significantly correlated with hospitalization and a lower hemoglobin level (p < 0.001). We did not find any significant differences between adolescents with or without a bleeding disorder regarding age of presentation, time from menarche, BAT, hemoglobin, or platelet count.Conclusion: Our findings revealed the clinical presentations and treatments of adolescents with HMB are similar, regardless of the presence of a bleeding disorder. This emphasizes the importance of thorough evaluation in all adolescents presenting with HMB.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-8"},"PeriodicalIF":1.7,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12060817/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143639357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Need for Concurrent Chemoimmunotherapy in Pediatric B-Cell Lymphoblastic Leukemia. 儿童b细胞淋巴细胞白血病同步化疗免疫治疗的必要性。

IF 1.7 4区医学

Acta Haematologica Pub Date : 2025-03-07 DOI: 10.1159/000545028

David McCall, Seth E Karol, Nicholas J Short

引用次数: 0

ECLIPSE-PV: A Randomized, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft in Polycythemia Vera. ECLIPSE-PV：一项随机、多中心研究，评估两种给药方案对真性红细胞增多症的有效性、安全性和耐受性。

IF 1.7 4区医学

Acta Haematologica Pub Date : 2025-03-05 DOI: 10.1159/000544818

John Mascarenhas, Prithviraj Bose, Christopher Hillis, Abdulraheem Yacoub, Firas El Chaer, Dawn Maze, Ghaith Abu-Zeinah, Albert Qin, Victor Priego, Tsewang Tashi, Sonia Cerquozzi, Sunil Babu, Lynda Foltz, Swati Goel, Rupali R Bhave, Stephanie Lee, Stephen T Oh, Brandi Reeves, Christopher Benton, Luke Fletcher, Shireen Sirhan, Hana Safah, Hayman Salib, Pierre J A Villeneuve, Oleh Zagrijtschuk, Henry Castro, Lucia Masarova

{"title":"ECLIPSE-PV: A Randomized, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft in Polycythemia Vera.","authors":"John Mascarenhas, Prithviraj Bose, Christopher Hillis, Abdulraheem Yacoub, Firas El Chaer, Dawn Maze, Ghaith Abu-Zeinah, Albert Qin, Victor Priego, Tsewang Tashi, Sonia Cerquozzi, Sunil Babu, Lynda Foltz, Swati Goel, Rupali R Bhave, Stephanie Lee, Stephen T Oh, Brandi Reeves, Christopher Benton, Luke Fletcher, Shireen Sirhan, Hana Safah, Hayman Salib, Pierre J A Villeneuve, Oleh Zagrijtschuk, Henry Castro, Lucia Masarova","doi":"10.1159/000544818","DOIUrl":"10.1159/000544818","url":null,"abstract":"Introduction: Ropeginterferon alfa-2b-njft (ropeg) was approved and recommended as a preferred cytoreductive treatment for polycythemia vera (PV). The approved regimen requires an initial dose of 100 μg or 50 μg if transitioning from hydroxyurea (HU) and up-titrations of 50 μg every 2 weeks to 500 μg maximumly. The time to achieve the plateau dose takes approximately 20 weeks. This study compares the approved regimen with a higher initial dose and accelerated dose titration (HIDAT) regimen.Methods: ECLIPSE-PV is a randomized, open-label, multicenter trial in patients with PV in the USA and Canada. Patients received ropeg either per the approved dosing schema or HIDAT regimen, i.e., 250 μg on day 0, 350 μg at week 2, and 500 μg from week 4 thereafter if tolerable. The primary endpoint is complete hematologic response (CHR) rate at week 24. CHR is defined as hematocrit <45%, white blood cells <10 × 109/L, platelets ≤400 × 109/L without phlebotomy in the previous 12 weeks. Secondary endpoints include molecular response, safety, tolerability, and quality of life.Conclusion: A total of 111 patients were randomized and the last patient was enrolled on June 21, 2024. As of November 12, 2024, the discontinuation rate was 14.4%, and 16 patients (14.4%) completed the study. The study is expected to be completed in the summer of 2025. This is the first prospective trial comparing two dosing regimens of ropeg. The results will inform the optimal treatment strategy for patients with PV.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-7"},"PeriodicalIF":1.7,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143565754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Distress and Care Utilization in Patients with Myeloproliferative Neoplasms. 骨髓增生性肿瘤患者的苦恼与护理利用。

IF 1.7 4区医学

Acta Haematologica Pub Date : 2025-02-12 DOI: 10.1159/000544162

Rushil Virendra Patel, Danielle Boselli, Patrick L Meadors, Stephanie Begley, Rupali Bose, Jing Ai, Brittany Knick Ragon, Srinivasa Sanikommu, Nilay Shah, Thomas Knight, James T Symanowski, Declan Walsh, Ruben A Mesa, Michael R Grunwald, Aleksander Chojecki

{"title":"Distress and Care Utilization in Patients with Myeloproliferative Neoplasms.","authors":"Rushil Virendra Patel, Danielle Boselli, Patrick L Meadors, Stephanie Begley, Rupali Bose, Jing Ai, Brittany Knick Ragon, Srinivasa Sanikommu, Nilay Shah, Thomas Knight, James T Symanowski, Declan Walsh, Ruben A Mesa, Michael R Grunwald, Aleksander Chojecki","doi":"10.1159/000544162","DOIUrl":"10.1159/000544162","url":null,"abstract":"Introduction: Distress negatively affects cancer outcomes. The National Comprehensive Cancer Network (NCCN) recommends screening patients for distress by a self-reported scale (0-10) and referring those with scores ≥4 to supportive services (SSs). Little is known about the prevalence of distress and healthcare utilization in classical Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs): polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis (MF).Methods: We retrospectively identified MPN patients at our center to measure the proportions of patients with distress ≥4 evaluated by a SS (chaplaincy, integrative oncology, palliative medicine, psychiatry, psychology, and social work [SW]) or had acute care utilization (ACU; ≥ 1 ED visit or hospitalization) within 6 months of electronic distress screening (EDS). We also obtained sociodemographic, disease characteristics, and symptom score data to stratify variables associated with distress.Results: Among 141 patients (44 PV, 49 ET, and 48 MF), the median age was 63 years (range, 25-89). Most patients identified as female (62%), white (77%), and completed EDS within 3 months of diagnosis (55%). Of 75/141 (53%) who reported distress ≥4, only 25/75 (33%) were evaluated by SS, and 23/75 (31%) had ACU within 6 months of EDS. Patients with distress ≥4 evaluated by SS had significantly higher ACU (48% vs. 14%; p = 0.009). Distress was associated with higher symptom scores and more ED visits but not gender, race, ethnicity, diagnosis, relationship status, or insurance.Conclusion: Despite consensus recommendations, most patients with distress ≥4 were not evaluated by SS. Future work should identify ways to better use patient-reported outcomes to promote early intervention.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-9"},"PeriodicalIF":1.7,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143405127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0